175 related articles for article (PubMed ID: 26691890)
21. Identification of Rare Variants Predisposing to Thyroid Cancer.
Wang Y; Liyanarachchi S; Miller KE; Nieminen TT; Comiskey DF; Li W; Brock P; Symer DE; Akagi K; DeLap KE; He H; Koboldt DC; de la Chapelle A
Thyroid; 2019 Jul; 29(7):946-955. PubMed ID: 30957677
[No Abstract] [Full Text] [Related]
22. Pitfalls of exome sequencing: a case study of the attribution of HABP2 rs7080536 in familial non-medullary thyroid cancer.
Gerhard GS; Bann DV; Broach J; Goldenberg D
NPJ Genom Med; 2017; 2():. PubMed ID: 28884020
[TBL] [Abstract][Full Text] [Related]
23. RE: HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.
Simeone P; Alberti S
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27418631
[No Abstract] [Full Text] [Related]
24. RE: HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.
Carvajal-Carmona LG; Tomlinson I; Sahasrabudhe R
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27154966
[No Abstract] [Full Text] [Related]
25. FOXE1 polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility.
Tomaz RA; Sousa I; Silva JG; Santos C; Teixeira MR; Leite V; Cavaco BM
Clin Endocrinol (Oxf); 2012 Dec; 77(6):926-33. PubMed ID: 22882326
[TBL] [Abstract][Full Text] [Related]
26. The FOXE1 locus is a major genetic determinant for familial nonmedullary thyroid carcinoma.
Bonora E; Rizzato C; Diquigiovanni C; Oudot-Mellakh T; Campa D; Vargiolu M; Guedj M; ; McKay JD; Romeo G; Canzian F; Lesueur F
Int J Cancer; 2014 May; 134(9):2098-107. PubMed ID: 24127282
[TBL] [Abstract][Full Text] [Related]
27. Clinically-relevant Germline Variants in Children with Non-Medullary Thyroid Cancer.
van der Tuin K; Ruano D; Knijnenburg J; van der Luijt RB; Morreau H; Links TP; Hes FJ;
J Clin Endocrinol Metab; 2024 Feb; ():. PubMed ID: 38415346
[TBL] [Abstract][Full Text] [Related]
28. Aryl hydrocarbon receptor interacting protein mutations seem not to associate with familial non-medullary thyroid cancer.
Raitila A; Georgitsi M; Bonora E; Vargiolu M; Tuppurainen K; Mäkinen MJ; Vierimaa O; Salmela PI; Launonen V; Vahteristo P; Aaltonen LA; Romeo G; Karhu A
J Endocrinol Invest; 2009 May; 32(5):426-9. PubMed ID: 19794292
[TBL] [Abstract][Full Text] [Related]
29. Digoxin treatment reactivates in vivo radioactive iodide uptake and correlates with favorable clinical outcome in non-medullary thyroid cancer.
Crezee T; Tesselaar MH; Nagarajah J; Corver WE; Morreau J; Pritchard C; Kimura S; Kuiper JG; van Engen-van Grunsven I; Smit JWA; Netea-Maier RT; Plantinga TS
Cell Oncol (Dordr); 2021 Jun; 44(3):611-625. PubMed ID: 33534128
[TBL] [Abstract][Full Text] [Related]
30. Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer.
Hińcza K; Kowalik A; Kowalska A
Genes (Basel); 2019 Jun; 10(7):. PubMed ID: 31247975
[TBL] [Abstract][Full Text] [Related]
31. Non-medullary Thyroid Cancer Susceptibility Genes: Evidence and Disease Spectrum.
Zhou J; Singh P; Yin K; Wang J; Bao Y; Wu M; Pathak K; McKinley SK; Braun D; Lubitz CC; Hughes KS
Ann Surg Oncol; 2021 Oct; 28(11):6590-6600. PubMed ID: 33660127
[TBL] [Abstract][Full Text] [Related]
32. Risk of thyroid cancer in first-degree relatives of patients with non-medullary thyroid cancer by histology type and age at diagnosis: a joint study from five Nordic countries.
Fallah M; Pukkala E; Tryggvadottir L; Olsen JH; Tretli S; Sundquist K; Hemminki K
J Med Genet; 2013 Jun; 50(6):373-82. PubMed ID: 23585692
[TBL] [Abstract][Full Text] [Related]
33. Familial nonmedullary thyroid carcinoma.
Malchoff CD; Malchoff DM
Cancer Control; 2006 Apr; 13(2):106-10. PubMed ID: 16735984
[TBL] [Abstract][Full Text] [Related]
34. Genetic heterogeneity in familial nonmedullary thyroid carcinoma: exclusion of linkage to RET, MNG1, and TCO in 56 families. NMTC Consortium.
Lesueur F; Stark M; Tocco T; Ayadi H; Delisle MJ; Goldgar DE; Schlumberger M; Romeo G; Canzian F
J Clin Endocrinol Metab; 1999 Jun; 84(6):2157-62. PubMed ID: 10372725
[TBL] [Abstract][Full Text] [Related]
35. Familial Aggregation and Heritability of Nonmedullary Thyroid Cancer in an Asian Population: A Nationwide Cohort Study.
Lin HT; Liu FC; Lin SF; Kuo CF; Chen YY; Yu HP
J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32333767
[TBL] [Abstract][Full Text] [Related]
36. Whole Genome Sequencing of Familial Non-Medullary Thyroid Cancer Identifies Germline Alterations in MAPK/ERK and PI3K/AKT Signaling Pathways.
Srivastava A; Kumar A; Giangiobbe S; Bonora E; Hemminki K; Försti A; Bandapalli OR
Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31614935
[TBL] [Abstract][Full Text] [Related]
37. Familial nonmedullary thyroid carcinoma.
Malchoff CD; Malchoff DM
Semin Surg Oncol; 1999; 16(1):16-8. PubMed ID: 9890735
[TBL] [Abstract][Full Text] [Related]
38. In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease.
Mazeh H; Benavidez J; Poehls JL; Youngwirth L; Chen H; Sippel RS
Thyroid; 2012 Jan; 22(1):3-8. PubMed ID: 22136209
[TBL] [Abstract][Full Text] [Related]
39. Hyaluronan-binding protein 2 (HABP2) gene variation in women with recurrent miscarriage.
Husseini-Akram F; Haroun S; Altmäe S; Skjöldebrand-Sparre L; Åkerud H; Poromaa IS; Landgren BM; Stavreus-Evers A
BMC Womens Health; 2018 Aug; 18(1):143. PubMed ID: 30143058
[TBL] [Abstract][Full Text] [Related]
40. Clinical characteristics and disease outcome of patients with non-medullary thyroid cancer and brain metastases.
Slutzky-Shraga I; Gorshtein A; Popovitzer A; Robenshtok E; Tsvetov G; Akirov A; Hirsch D; Benbassat C
Oncol Lett; 2018 Jan; 15(1):672-676. PubMed ID: 29387239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
